Scarica l'app Stockscreener
1.295
1.89%
-0.025
Milestone Pharmaceuticals Inc Borsa (MIST) Ultime notizie
Milestone lures six new employees with 288,000 options - Stock Titan
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Enterprise value to EBIT forward of Milestone Pharmaceuticals Inc. – NASDAQ:MIST - TradingView
Enterprise value to EBIT forward of Milestone Pharmaceuticals Inc. – BOATS:MIST - TradingView
Price to sales forward of Milestone Pharmaceuticals Inc. – NASDAQ:MIST - TradingView
Price to sales forward of Milestone Pharmaceuticals Inc. – BOATS:MIST - TradingView
Enterprise value to revenue forward of Milestone Pharmaceuticals Inc. – BOATS:MIST - TradingView
Price to earnings forward of Milestone Pharmaceuticals Inc. – BOATS:MIST - TradingView
Milestone Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:MIST) - TradingView
MIST Forecast — Price Target — Prediction for 2027 - TradingView
Phio Pharmaceuticals Reaches Key Milestone in Advancing Lead Candidate PH-762 - TMX Newsfile
Milestone Pharmaceuticals (MIST) Investor update Summary - Quartr
Milestone Pharmaceuticals Inc (MIST) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Milestone Pharmaceuticals Inc - TradingKey
Milestone Pharmaceuticals Inc (MIST) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Milestone Pharmaceuticals Inc (MIST) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Milestone Pharmaceuticals Inc (MIST) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Milestone Pharmaceuticals Inc (MIST) Institutional Confidence - TradingKey
Milestone Pharmaceuticals Inc (MIST) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Milestone Pharmaceuticals Inc (MIST) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Milestone Pharmaceuticals Inc (MIST) Valuation: PE, PB & Fair Value Analysis - TradingKey
Milestone Pharmaceuticals Shareholders Approve Governance and Compensation Measures - The Globe and Mail
Milestone Pharmaceuticals Faces Financial Challenges amidst Market Shifts - timothysykes.com
Milestone Pharmaceuticals (MIST) investors approve equity plan, elect board and ratify PwC - Stock Titan
Milestone (NASDAQ: MIST) director receives 77,000 stock options grant - Stock Titan
Milestone Pharmaceuticals (MIST) director receives 77,000 stock options at $1.22 strike - Stock Titan
Milestone Pharmaceuticals (MIST) awards director 77,000 stock options - Stock Titan
Milestone Pharmaceuticals (MIST) director receives 77,000 stock options at $1.22 - Stock Titan
Director at Milestone Pharmaceuticals (MIST) receives 77,000 stock options at $1.22 - Stock Titan
Milestone Pharmaceuticals (NASDAQ: MIST) director receives 77,000 stock options grant - Stock Titan
Milestone Pharmaceuticals (MIST) director receives grant of 77,000 stock options - Stock Titan
Milestone Pharmaceuticals: Here Comes The Revenue Ramp (NASDAQ:MIST) - Seeking Alpha
Novartis Canada and the pan-Canadian Pharmaceutical Alliance Achieve Milestone Agreement Enabling Public Reimbursement of (pr)Scemblix® (asciminib tablets) - Newswire Canada
Milestone Pharmaceuticals: Taking The Long View (NASDAQ:MIST) - Seeking Alpha
Eli Lilly scores a first in major pharma milestone - thestreet.com
Heart Rhythm Society and Milestone Pharmaceuticals Partner to Expand SVT Patient Education Through UpBeat.org - PR Newswire
Wockhardt's Zaynich wins US FDA approval, marking milestone in antibiotic innovation - Business Today
Milestone (MIST) Q1 2026 Earnings Transcript - The Globe and Mail
Milestone Pharmaceuticals Inc. Q1 2026 Earnings: Significant EPS Miss as Pre-Revenue Biotech Continues DevelopmentRevenue Growth Outlook - dars.gov.et
Anti-Aging Cell Therapy Reaches Major GMP Milestone as Wave of Clinical Advancements Gain Momentum - PR Newswire
Analysts Offer Insights on Healthcare Companies: Alpha Tau Medical Ltd (DRTS), Neurogene (NGNE) and Milestone Pharmaceuticals (MIST) - The Globe and Mail
MISTMilestone Pharmaceuticals Inc Short Interest - Finviz
[EFFECT] Milestone Pharmaceuticals Inc. SEC Filing - Stock Titan
H.C. Wainwright Maintains Milestone Pharmaceuticals(MIST.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Milestone Pharmaceuticals (MIST) Slides 7.24% as Selling Pressure Builds—Key Support at $1.34 in FocusOBV Divergence - thelegaladvocate.com
Milestone Pharmaceuticals Q1 earnings call highlights - MSN
MIST Stock Price, Quote & Chart | MILESTONE PHARMACEUTICALS IN (NASDAQ:MIST) - ChartMill
Supernus Pharmaceuticals to make $33.4 million CVR milestone payment - Investing.com
Milestone reports Q1 results, highlights initial CARDAMYST sales - MSN
Milestone Pharmaceuticals Q1 2026 earnings preview - MSN
Milestone outlines ~2-year phase III AFib-RVR timeline as CARDAMYST launch reaches ~600 prescriptions - MSN
Milestone Pharmaceuticals (MIST) reports Q1 loss, lags revenue estimates - MSN
RTW Investments (MIST) and Roderick Wong disclose 9.99% ownership - Stock Titan
Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) Path To Profitability - Yahoo Finance
Milestone Pharmaceuticals Inc. (NASDAQ:MIST): Is Breakeven Near? - simplywall.st
MIST Maintained by Wells Fargo -- Price Target Lowered to $7.00 - GuruFocus
Milestone Pharmaceuticals Is Maintained at Overweight by Wells Fargo - Moomoo
Wells Fargo & Company Issues Pessimistic Forecast for Milestone Pharmaceuticals (NASDAQ:MIST) Stock Price - MarketBeat
Milestone Pharmaceuticals Inc.Common Shares (NQ: MIST - FinancialContent
1.60%
3.59%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):